US Patent

US12377133 — Dry pharmaceutical formulations of CNP conjugates

Method of Use · Assigned to Ascendis Pharma Growth Disorders AS · Expires 2042-11-12 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a dry pharmaceutical formulation that includes a CNP conjugate, a buffering agent, and a bulking agent.

USPTO Abstract

A dry pharmaceutical formulation, wherein the pharmaceutical formulation comprises a CNP conjugate, a buffering agent and a bulking agent and wherein the CNP conjugate comprises a CNP moiety that is covalently and reversibly conjugated to a polymeric moiety.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4425`	—
`U-4425`	—
`U-4425`	—

Patent Metadata

Patent number: US12377133
Jurisdiction: US
Classification: Method of Use
Expires: 2042-11-12
Drug substance claim: No
Drug product claim: Yes
Assignee: Ascendis Pharma Growth Disorders AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.